Christopher M. O'Connor, MD, FACC
Dr. O’Connor is the CEO and Executive Director of the Inova Heart & Vascular Institute in Fairfax, VA. He previously served as director of the Duke Heart Center and chief of the Divisions of Cardiology and Clinical Pharmacology at Duke University Medical Center. A Fellow of the American College of Cardiology (ACC), the American Heart Association, and the European Society of Cardiology, he has served on over 90 CEC and DSMC committees in 25 years and served as chair or co-chair on more than 15 of these committees. He has an extensive record of successful mentorship of trainees and has published over 400 manuscripts.
He has served as principal investigator (PI) or co-PI for over 20 national and international clinical trials with an extensive record of NIH/NHLBI and industry grants, including the NIH Heart Failure Network Core Skills Development Training Grant, focused on the training of future cardiovascular (CV) investigators. He was PI of the ASCEND-HF Trial, the largest acute heart failure trial ever conducted. He has served as PI for a number of other CV trials, including the NHLBI sponsored HF-ACTION Trial, the largest prospective randomized trial examining the effects of lifestyle intervention on outcomes in heart failure patients. Dr. O’Connor was also the lead investigator in the WIZARD Trial, a trial of antibiotic therapy in stable ischemic heart disease; SADHART, a randomized trial of antidepressant therapy in depressed post myocardial infarction patients; the ACTIV Trial, a randomized trial of vasopressin antagonists in moderate congestive heart failure; and RITZ 4, a trial of IV endothelin antagonists in acute heart failure. He is currently PI of the CAT-HF Trial, the largest trial in the U.S. examining the treatment of sleep apnea in heart failure patients.
Dr. O’Connor’s research interests include: acute heart failure, co-morbidities in heart failure, clinical trials, biomarkers, and novel pharmacological and non-pharmacological approaches for the treatment of heart failure.
Dr. O’Connor’s research interests include: acute heart failure, co-morbidities in heart failure, clinical trials, biomarkers, and novel pharmacological and non-pharmacological approaches for the treatment of heart failure. Dr. O’Connor completed his undergraduate and medical school training at the University of Maryland. He completed his Internal Medicine residency and Cardiology Fellowships at Duke University Medical Center. He is a professor of medicine and associate professor in psychiatry and behavior sciences.